What Rapid Dose Therapeutics does

Rapid Dose Therapeutics Corp. is a Canadian pharma-technology company that has developed QuickStrip™, an orally dissolvable thin film platform that delivers active pharmaceutical ingredients through the oral mucosa with absorption kinetics the company claims are comparable to intravenous injection. The platform is applied across multiple verticals: over-the-counter consumer products (Energy, B12, Sleep) sold direct-to-consumer via QuickStrip.life, dental products (Lidocaine QuickStrip™ for anesthesia distributed via Skycare Compounding Labs, and XyliStrip for xerostomia), pharmaceutical applications under the PharmaStrip™ brand, medical cannabis (launched in Brazil via Entourage Phytolab partnership following ANVISA approval), and nicotine replacement therapy products (NicStrip™) co-developed with a major global tobacco company and submitted to Health Canada. The proprietary RDMx formulation underpins all product variants, and the company holds an Indian patent (IN 582202) for its nicotine bilayer oral film with two WIPO PCT filings covering up to 158 potential jurisdictions.

The company generates revenue through a mix of B2B licensing and producer agreements (Platinum and Gold Programs granting partners production rights, RDMx formulation access, and QuickStrip™ trademark co-labeling), pre-commercialization development fees from pharmaceutical partners (including a monthly USD $120,000 fee arrangement with its global tobacco partner through mid-2025 and up to ~$1.8M CAD in committed funding), OTC e-commerce sales, and research collaboration grants. RDT serves four primary customer segments: pharmaceutical companies seeking novel drug delivery formats for existing APIs, tobacco/nicotine companies pursuing smoke-free alternatives, medical cannabis operators in regulated markets, and dental professionals. The company is headquartered in Burlington, Ontario, operates from a facility undergoing clean room upgrades for Health Canada Drug Establishment Licence and EU GMP compliance, and is publicly listed on the Canadian Securities Exchange (CSE: DOSE) and US OTCQB (RDTCF), with a capital structure of 131.9 million common shares outstanding as of November 2024.

Strategically, RDT has pursued geographic and vertical diversification through partnerships rather than direct market entry: Aavishkar Oral Strips for India manufacturing and patent prosecution, Entourage Phytolab and Nexxions for Brazil and US medical cannabis distribution, Eco Canadian Organic for harm reduction applications, and academic collaborations with the University of Regina, University of Saskatchewan, and McMaster University for clinical validation. The company's growth model relies on regulatory approvals (Health Canada for nicotine, ANVISA for cannabis, EU GMP for pharmaceutical-grade production) translating into licensing and royalty streams from partners that handle regional manufacturing and distribution.

Name

Rapid Dose Therapeutics

Legal name

Rapid Dose Therapeutics Corp.

Website

https://rapid-dose.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Rapid Dose Therapeutics is a Canadian pharma-technology company that has developed QuickStrip™, an orally dissolvable thin film drug delivery platform applied across OTC, dental, pharmaceutical, medical cannabis, and nicotine replacement verticals through B2B licensing partnerships and direct-to-consumer e-commerce.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology / Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Toilet Preparation Manufacturing (32562), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening) (CRADAMAA)

akta.pro secondary industries

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

Keywords

• Oral thin film drug delivery
• Pharmaceutical drug delivery
• Oral dissolvable strips
• Nicotine replacement therapy
• Medical cannabis delivery

Headquarters

HQ city

Burlington

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Product Sales (OTC and Direct): Sale of over-the-counter QuickStrip™ products (Energy, B12, Sleep, Dental) directly to consumers via QuickStrip.life and through retail/partnership channels.
2. Licensing and Producer Agreements: Platinum and Gold Producer Agreements grant partners rights to use RDT's proprietary production, RDMx formulation, QuickStrip™ trademark, and co-labeling rights in exchange for licensing fees and supply arrangements.
3. Pharmaceutical Development Partnerships: Co-development and pre-commercialization agreements with pharmaceutical, cannabis, and nicotine partners (e.g., global tobacco company), generating monthly fees and milestone payments for product development, regulatory submissions, and clinical trials.
4. Research Collaborations and Grants: NFL-funded clinical research with University of Regina and University of Saskatchewan; Mitacs Accelerate Grant for vaccine delivery research; Health Canada-funded harm reduction pilot project.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

Rapid Dose Therapeutics develops and commercializes a proprietary QuickStrip™ oral thin film drug delivery platform that rapidly releases active pharmaceutical ingredients through the oral mucosa into the bloodstream, with absorption kinetics comparable to intravenous injection. The company sells over-the-counter consumer products (Energy, B12, Sleep), dental products (Lidocaine QuickStrip™, XyliStrip), pharmaceutical applications (NicStrip™ nicotine replacement, PharmaStrip™), and medical cannabis products, while licensing its technology and RDMx formulation to partners under Platinum and Gold Producer Agreements.

Product overview

Rapid Dose Therapeutics offers a portfolio of products centered on its proprietary QuickStrip™ oral thin film drug delivery technology platform. The core QuickStrip™ technology enables rapid delivery of pharmaceuticals, nutraceuticals, and active ingredients through the oral mucosa, with absorption speeds comparable to intravenous administration. The product line spans OTC consumer products (QuickStrip™ Energy, B12, Sleep), dental products (Lidocaine QuickStrip™ for anesthesia, XyliStrip for dry mouth), pharmaceutical applications (NicStrip™ nicotine replacement, PharmaStrip™), and medical cannabis products. The company also offers partnership programs (Platinum and Gold) for manufacturers seeking to use its proprietary technology. Manufacturing capabilities are headquartered in Burlington, Ontario with global expansion through partnerships in India (Aavishkar Oral Strips) and Brazil (Entourage Phytolab).

Differentiator

Problem solved

Functional benefit

Brands

• QuickStrip: Oral thin film drug delivery technology platform for pharmaceuticals, nutraceuticals, and cannabis products
• XyliStrip
• LQS (Lidocaine QuickStrip)
• NicStrip
• Replace+

Products and services

• QuickStrip™ Energy Over-the-counter energy product delivered via oral thin film strip for rapid onset of energy effects, sold to adult consumers through the QuickStrip.life e-commerce storefront.
• QuickStrip™ B12 Over-the-counter Vitamin B12 supplement delivered via dissolvable oral thin film strip for improved absorption compared to traditional oral dosage, sold direct-to-consumer through QuickStrip.life.
• QuickStrip™ Sleep Over-the-counter melatonin product delivered via oral thin film strip designed to support sleep onset, sold direct-to-consumer through QuickStrip.life.
• LQS (Lidocaine QuickStrip™) Muco-adhesive oral thin film developed with Skycare Compounding Labs that adheres to oral mucosa upon contact and delivers lidocaine for rapid-onset local dental anesthesia as an alternative to topical gels and injectable carpules.
• XyliStrip Oral dissolving thin film strip containing xylitol for dental professionals to support patients experiencing dry mouth (xerostomia), distributed through Canadian dental tradeshows and compounding pharmacy partners.
• NicStrip™ (QuickStrip™ Nicotine) Nicotine replacement therapy delivered via oral thin film in 1mg, 2mg, 3mg, and 4mg formats, designed to mimic the nicotine absorption curve of cigarettes without combustion byproducts for smoking cessation and harm reduction, co-developed with a major global tobacco partner.
• QuickStrip™ Medical Cannabis Medical cannabis oral thin film product launched in Brazil following ANVISA approval for sublingual and buccal formats, co-branded with Entourage Phytolab, representing one of the first oral dissolvable strip medical cannabis products in Brazil's healthcare market.
• Replace+ Sublingual cannabis strip developed with Eco Canadian Organic Inc. using QuickStrip™ technology for harm reduction, designed for fast-acting, convenient, and precise delivery to support individuals transitioning away from opioid dependence.
• PharmaStrip™ Pharmaceutical-grade version of the QuickStrip™ platform offered to pharmaceutical partners that can be deployed as a device instead of a drug to reduce time and cost of bringing new products to market or to extend product lines within an existing approved API.
• QuickStrip™ Platform (Core Technology Offering) Core orally dissolvable thin film drug delivery technology platform that rapidly dissolves to deliver pharmaceuticals, nutraceuticals, and active ingredients through the oral mucosa directly into the bloodstream with absorption kinetics comparable to intravenous injection, licensed to partners and used as the basis for all RDT products.

Quantifiable outcome

• QuickStrip™ delivery mimics blood concentration profiles comparable to intravenous injection
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered secondary, core, flagship and major.

• McMaster UniversitysecondaryStrategic or Co-development Partner · 26 March 2026Academic research collaboration on oral thin film drug delivery, including incorporation of Loratadine-Cyclodextrin Complexes in oral thin films for rapid drug delivery. Study published results in Frontiers in Pharmacology.
• Aavishkar Oral Strips Pvt. Ltd.coreTechnology or Integration · 5 March 2026Indian pharmaceutical partner for oral thin film technology. RDT partnered with Aavishkar to file and secure Indian Patent No. IN 582202 for Nicotine Bilayer Oral Film, and jointly filed two international PCT applications for nicotine delivery technology covering dissolvable and non-dissolvable oral strips. Aavishkar serves as RDT's manufacturing partner for nicotine products targeting global markets.
• Entourage PhytolabflagshipChannel Partner/ Reseller/ Distributor · 10 February 2026Brazilian pharmaceutical company partner for manufacturing and commercial distribution of QuickStrip™ medical cannabis oral thin film in Brazil following ANVISA approval. RDT launched its co-branded product in Brazil's healthcare market through this partnership, making RDT among the first to introduce an oral dissolvable strip medical cannabis product to Brazil.
• NexxionsmajorChannel Partner/ Reseller/ Distributor · 10 February 2026US-based distribution partner working with RDT and Entourage Phytolab for the Brazil medical cannabis product launch. Nexxions provides US distribution capabilities supporting the QuickStrip™ medical cannabis expansion into Brazil's growing medical cannabis market.
• Major Global Tobacco CompanycoreStrategic or Co-development Partner · 20 October 2025RDT is in its fourth year of collaboration with a major global tobacco company to develop and commercialize NicStrip™/QuickStrip™ nicotine products. The partnership includes ongoing pharmacokinetic trials, Health Canada regulatory submission, and product development. Financial commitment of up to approximately $1.8 million CAD supports the collaboration extended for seven additional months.
• Eco Canadian Organic Inc. (ECO)majorStrategic or Co-development Partner · 29 July 2025Partner in the Health Canada-funded SUAP Harm Reduction Pilot Project for First Nations communities combating opioid addiction. ECO developed Replace+, a sublingual cannabis strip using RDT's QuickStrip™ technology, as a harm reduction tool. The two-year pilot project addresses Canada's opioid crisis in Indigenous communities.
• University of ReginamajorStrategic or Co-development Partner · 29 May 2024Research partner led by Dr. J. Patrick Neary conducting an NFL-funded randomized clinical study comparing CBD bioavailability via QuickStrip™ oral thin film versus traditional oral dosage. The study examines naturally produced cannabinoids for pain management and neuroprotection related to concussion and contact sports.
• University of SaskatchewanmajorStrategic or Co-development Partner · 29 May 2024Research partner led by Dr. Jane Alcorn participating in the NFL-funded clinical research program examining CBD bioavailability and concussion/neuroprotection using RDT's QuickStrip™ delivery platform.
• Skycare Compounding LabsmajorChannel Partner/ Reseller/ Distributor · 15 May 2024Canadian compounding pharmacy partner for LQS (Lidocaine QuickStrip™) dental product distribution. Skycare produces and fulfills LQS orders for dental professionals across Canada. Partnership enables direct-to-dentist sales of muco-adhesive oral thin film lidocaine strips.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• IntelGenx Technologies: Canadian-listed (TSXV: IGX) oral thin film drug delivery developer with a similar partner-licensing model and product applications in pharmaceutical and OTC markets. Comparable size, public status, and business model to RDT.
• LTS Lohmann Therapie-Systeme: German global leader in oral thin film and transdermal drug delivery systems, supplying pharmaceutical partners worldwide. Comparable to RDT as a contract drug delivery platform provider with pharma licensing model.
• ZIM Laboratories: India-based oral thin film drug delivery company with multiple commercialized OTF products and partnerships with global pharma companies. Comparable to RDT in technology focus and emerging market footprint.
• Aquestive Therapeutics: US-listed (NASDAQ: AQST) oral thin film drug delivery company that developed the Suboxone sublingual film and is commercializing Libervant. Most directly comparable to RDT in technology, regulatory pathway, and licensing model.
• Tapemark: US-based CDMO specializing in oral thin film and transdermal drug delivery for pharma partners. Comparable to RDT in pharmaceutical OTF manufacturing and partner-based go-to-market.

Emerging players

• NJOY: US-listed smoke-free nicotine products company focused on e-vapor and alternatives to combustible cigarettes. Comparable to RDT as a regulated nicotine delivery challenger operating in the same smoke-free market.
• SkyCare Compounding Labs / DentaQuest: Regional dental product and compounding partners where RDT's XyliStrip and LQS products are sold. Comparable as adjacent dental product channel participants in the same Canadian dental tradeshow ecosystem.

Broad incumbents

• Haleon: Global OTC consumer healthcare company (Sensodyne, Centrum, Advil). Comparable as a large-scale OTC platform that could license or in-license novel delivery formats like QuickStrip™ for its consumer health portfolio.
• Philip Morris International: Global tobacco major driving smoke-free nicotine transformation (IQOS, ZYN). Relevant as the archetype of the strategic partner RDT's global tobacco collaborator resembles, and as the end customer for OTF nicotine delivery.
• Jazz Pharmaceuticals: Specialty pharma with cannabis-derived Epidiolex. Comparable to RDT as a regulated cannabis pharmaceutical player that validates clinical-grade delivery formats for the category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/RapidDose
• YouTubeyoutube.com/channel/UCALNpYQswp-aNB3Gnm36gJQ
• Facebookbusiness.facebook.com/RapidDoseTherapeutics/?business_id=1693926260858274
• LinkedInlinkedin.com/company/rapid-dose-therapeutics-rdt

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapid Dose Therapeutics